Dear AMN men
Certainly an exciting time for Minoryx and Swan Bio!
As you all have learned, though, while we share many attributes of the disease, all of us are special in our own way. It is because of this, I am thinking that it is going to take more than 1-2 solutions to solve our problem. It seems to me that the more therapeutics, the better.
So, with that in mind, I implore you all to do whatever you feel comfortable with, clinical study-wise, to move the science along.
After a 15 month journey, I today received my first dose in the VK0214-102 study. True enough, while I am not likely to see much benefit from this 28-day trial, it is about all that I can do to advance any AMN drug candidates.
I do not think that this one is not recruiting very rapidly. Please consider enrolling. If you are having trouble figuring out who to contact to get involved, please do let me know.
Keep it straight. Brad
Walking the Rails 